StreetAlpha.app
Home › Stocks › OPRX

OptimizeRx Corp (OPRX)

$6.70
▼ −4.42%
LAST CLOSE · NOV 20

OptimizeRx provides digital marketing and audience targeting technology that helps life sciences brands reach healthcare providers and patients. It last closed at $6.70 on Nov 20, down 4.42% on the day. The next earnings report for OPRX is expected around Thu, Mar 4, 2027, after the close. For the quarter ended Sep 2026, OPRX reported EPS of $0.06 on revenue of $21.6M, with revenue down 17.1% from a year ago. Over its last 8 reports the stock moved an average of 23.8% the session after earnings. Over the last 12 months OPRX insiders bought $0 of stock on the open market and sold $19K, according to SEC Form 4 filings.

AI Auto Pilots
Is OPRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OPRX.

Key Stats

Last 12 months
Results
Revenue
$94.2M
−14.0% vs a year ago
Net income
$5.0M
+14655.9% vs a year ago
EPS (diluted)
$0.26
+2500.0% vs a year ago
Free cash flow
$19.9M
21.1% margin
Valuation
Market cap
$126.7M
18.9M shares
P/E
25.8
Price over 12 month EPS
Price to sales
1.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$22.3M
At Sep 30
Debt
$13.4M
At Sep 30
Shareholder equity
$133.9M
Shares outstanding
18.9M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $61.3M$61.3MFY2021FY2022: $62.5M$62.5MFY2022FY2023: $71.5M$71.5MFY2023FY2024: $92.1M$92.1MFY2024FY2025: $109.4M$109.4MFY2025

From OPRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · After the close
Reported EPS
$0.06
Quarter ended Sep 2026
Year ago EPS
$0.04
+50.0% on a GAAP basis
Revenue
$21.6M
−17.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.00Dec '24Mar 2025: -$0.12Mar '25Jun 2025: $0.08Jun '25Sep 2025: $0.04Sep '25Dec 2025: $0.26Dec '25Mar 2026: -$0.03Mar '26Jun 2026: -$0.04Jun '26Sep 2026: $0.06Sep '26Latest $0.06
Revenue by quarter
Dec 2024: $32.3MDec '24Mar 2025: $21.9MMar '25Jun 2025: $29.2MJun '25Sep 2025: $26.1MSep '25Dec 2025: $32.2MDec '25Mar 2026: $19.8MMar '26Jun 2026: $20.5MJun '26Sep 2026: $21.6MSep '26Latest $21.6M
How OPRX moved after its last 8 reports
Average move the session after a report ±23.8%
Nov 13, 2026After the close−9.5%
Aug 12, 2026After the close+24.7%
May 12, 2026After the close−22.5%
Mar 5, 2026After the close−10.5%
Nov 6, 2025After the close−17.4%
Aug 7, 2025After the close+34.7%
May 12, 2025After the close+19.7%
Mar 12, 2025Time not announced+51.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on OPRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on OPRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OPRX

Technical Analysis

OPRX · as of the Nov 20 close · updated each morning
Turning down, nearing oversold

The stock is 27% below its 20 day and 25% below its 50 day average. It is 5% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the swing low (Aug 12) at $6.57, and the nearest resistance the Pivot at $6.79.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.3%/day
Key levels
$15.5952 week high+132.7%
$8.5320 day average+27.3%
$8.3850 day average+25.1%
$7.74100 day average+15.5%
$7.07200 day average+5.5%
$7.01Pivot R1+4.6%
$6.87Swing high (Jul 15)+2.5%
$6.79Pivot+1.3%
$6.70Last close
$6.57Swing low (Aug 12)−1.9%
$6.48Pivot S1−3.3%
$4.5452 week low−32.2%
Indicators
RSI (14)33.88Weak, oversold below 30Neutral
MACD-0.46Below its signal lineBearish
Stochastic18.9Near the bottom of its rangeOversold
ADX (14)29.1Trending down
Williams %R-89.7Oversold below −80, overbought above −20Oversold
CCI (20)-128.6Oversold below −100, overbought above 100Oversold
Rate of change−23.5%Change over 10 sessionsBearish
ATR (14)$0.69Typical daily range, 10.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OPRX

What happened before

See how OPRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OPRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OPRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OPRXHow many large options trades hit OPRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

OPRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼40 buying vs 62 selling
  • ▲Held by funds +5.3 pts
  • ▼Funds holding -10
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding103113−8.8%
In funds' top 10110.0%
Held by funds64.7%59.4%+5.3 pts
New / increased13 / 2722 / 33−27.3%
Reduced / sold out37 / 2542 / 37−21.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OPRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OPRX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$19K1 sale · 1 insider
2025-12 sold $19KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Dec 19, 2025Edward StelmakhChief Finance & Strat OfficerSale1,388$13.51$19K
Oct 3, 2025Stephen L SilvestroCEOSale1,620$18.75$30K
Aug 28, 2025Patrick D SpanglerDirectorSale11,120$17.49$194K
Mar 14, 2025James Paul LangDirectorBuy321,408$7.60$2.4M
Dec 12, 2024William J FebboCEOBuy20,000$5.01$100K
Every insider buy and sale for OPRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OPRX insider trades →

From SEC Form 4 filings by OPRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OPRX is in one of them and how their past OPRX trades turned out.

OPRX in the AI portfolios
Loading…

OPRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OPRX in an article yet. Here's the latest on the wider market.

OPRX in the news

About OptimizeRx

OptimizeRx is a healthcare technology company based in Waltham, Massachusetts. It sells digital marketing and engagement solutions to life sciences brands, helping them reach doctors, pharmacists and patients through electronic health record systems, prescribing platforms and consumer media channels. Its offerings include audience targeting tools, pharmacy stock alerts and copay offer information shown to prescribers at the point of care. Its customers are drug manufacturers and their agency partners.

Headquarters
Waltham, MA